BACKGROUND: Sleep-disordered breathing (SDB) is a treatable but markedly under-diagnosed condition of frequent breathing pauses during sleep. SDB is linked to incident cardiovascular disease, stroke, and other morbidity. However, the risk of mortality with untreated SDB, determined by polysomnography screening, in the general population has not been established. METHODS: An 18-year mortality follow-up was conducted on the population-based Wisconsin Sleep Cohort sample (n = 1522), assessed at baseline for SDB with polysomnography, the clinical diagnostic standard. SDB was described by the number of apnea and hypopnea episodes/hour of sleep; cutpoints at 5, 15 and 30 identified mild, moderate, and severe SDB, respectively. Cox proportional hazards regression was used to estimate all-cause and cardiovascular mortality risks, adjusted for potential confounding factors, associated with SDB severity levels. RESULTS: All-cause mortality risk, adjusted for age, sex, BMI, and other factors was significantly increased with SDB severity. The adjusted hazard ratio (HR, 95% CI) for all-cause mortality with severe versus no SDB was 3.0 (1.4,6.3). After excluding persons who had used CPAP treatment (n = 126), the adjusted HR (95% CI) for all-cause mortality with severe versus no SDB was 3.8 (1.6,9.0); the adjusted HR (95% CI) for cardiovascular mortality was 5.2 (1.4,19.2). Results were unchanged after accounting for daytime sleepiness. CONCLUSIONS: Our findings of a significant, high mortality risk with untreated SDB, independent of age, sex, and BMI underscore the need for heightened clinical recognition and treatment of SDB, indicated by frequent episodes of apnea and hypopnea, irrespective of symptoms of sleepiness.
BACKGROUND:Sleep-disordered breathing (SDB) is a treatable but markedly under-diagnosed condition of frequent breathing pauses during sleep. SDB is linked to incident cardiovascular disease, stroke, and other morbidity. However, the risk of mortality with untreated SDB, determined by polysomnography screening, in the general population has not been established. METHODS: An 18-year mortality follow-up was conducted on the population-based Wisconsin Sleep Cohort sample (n = 1522), assessed at baseline for SDB with polysomnography, the clinical diagnostic standard. SDB was described by the number of apnea and hypopnea episodes/hour of sleep; cutpoints at 5, 15 and 30 identified mild, moderate, and severe SDB, respectively. Cox proportional hazards regression was used to estimate all-cause and cardiovascular mortality risks, adjusted for potential confounding factors, associated with SDB severity levels. RESULTS: All-cause mortality risk, adjusted for age, sex, BMI, and other factors was significantly increased with SDB severity. The adjusted hazard ratio (HR, 95% CI) for all-cause mortality with severe versus no SDB was 3.0 (1.4,6.3). After excluding persons who had used CPAP treatment (n = 126), the adjusted HR (95% CI) for all-cause mortality with severe versus no SDB was 3.8 (1.6,9.0); the adjusted HR (95% CI) for cardiovascular mortality was 5.2 (1.4,19.2). Results were unchanged after accounting for daytime sleepiness. CONCLUSIONS: Our findings of a significant, high mortality risk with untreated SDB, independent of age, sex, and BMI underscore the need for heightened clinical recognition and treatment of SDB, indicated by frequent episodes of apnea and hypopnea, irrespective of symptoms of sleepiness.
Authors: T Hori; Y Sugita; E Koga; S Shirakawa; K Inoue; S Uchida; H Kuwahara; M Kousaka; T Kobayashi; Y Tsuji; M Terashima; K Fukuda; N Fukuda Journal: Psychiatry Clin Neurosci Date: 2001-06 Impact factor: 5.188
Authors: Virend K Somers; David P White; Raouf Amin; William T Abraham; Fernando Costa; Antonio Culebras; Stephen Daniels; John S Floras; Carl E Hunt; Lyle J Olson; Thomas G Pickering; Richard Russell; Mary Woo; Terry Young Journal: Circulation Date: 2008-08-25 Impact factor: 29.690
Authors: O Parra; A Arboix; S Bechich; L García-Eroles; J M Montserrat; J A López; E Ballester; J M Guerra; J J Sopeña Journal: Am J Respir Crit Care Med Date: 2000-02 Impact factor: 21.405
Authors: John Robbins; Susan Redline; Ann Ervin; Joyce A Walsleben; Jingzhong Ding; F Javier Nieto Journal: J Clin Sleep Med Date: 2005-04-15 Impact factor: 4.062
Authors: Andrew Cassar; Timothy I Morgenthaler; Ryan J Lennon; Charanjit S Rihal; Amir Lerman Journal: J Am Coll Cardiol Date: 2007-09-17 Impact factor: 24.094
Authors: Ilene M Rosen; Douglas B Kirsch; Kelly A Carden; Raman K Malhotra; Kannan Ramar; R Nisha Aurora; David A Kristo; Jennifer L Martin; Eric J Olson; Carol L Rosen; James A Rowley; Anita V Shelgikar Journal: J Clin Sleep Med Date: 2018-12-15 Impact factor: 4.062
Authors: Qiaoling Yao; Mi-Kyung Shin; Jonathan C Jun; Karen L Hernandez; Neil R Aggarwal; Jason R Mock; Jason Gay; Luciano F Drager; Vsevolod Y Polotsky Journal: J Lipid Res Date: 2013-02-05 Impact factor: 5.922
Authors: Joule J Li; Sarah L Appleton; Gary A Wittert; Andrew Vakulin; R Douglas McEvoy; Nick A Antic; Robert J Adams Journal: Sleep Date: 2014-03-01 Impact factor: 5.849
Authors: Luciano F Drager; Qiaoling Yao; Karen L Hernandez; Mi-Kyung Shin; Shannon Bevans-Fonti; Jason Gay; Thomas E Sussan; Jonathan C Jun; Allen C Myers; Gunilla Olivecrona; Alan R Schwartz; Nils Halberg; Philipp E Scherer; Gregg L Semenza; David R Powell; Vsevolod Y Polotsky Journal: Am J Respir Crit Care Med Date: 2013-07-15 Impact factor: 21.405